Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,977 public trials 2,028 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Not Yet Recruiting

Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma

NCT07758673

Conditions: Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +23 more
Locations: City of Hope Medical Center Duarte, California, United States

City of Hope at Irvine Lennar Irvine, California, United States

View Trial Details

Not Yet Recruiting

Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.

NCT07757412

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: AUH Aarhus, Denmark

OUH Odense, Denmark

North Estonia Medical Centre Tallinn, Estonia

Tartu University Hospital Tartu, Estonia

View Trial Details

Not Yet Recruiting

A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

NCT07667868

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)

NCT07009899

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Froedtert & the Medical College of Wisconsin Milwaukee, Wisconsin, United States

View Trial Details

Not Yet Recruiting

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT07221032

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Froedtert & the Medical College of Wisconsin Milwaukee, Wisconsin, United States

View Trial Details

Not Yet Recruiting

Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma

NCT07754682

Conditions: Antibiotic Prophylaxis, B Cell Acute Lymphoblastic Leukemia (B-ALL), B Cell Lymphoma, +19 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)

NCT07751471

Conditions: AL Amyloidosis, Amyloidosis, Immune System Diseases, +10 more
Locations: Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China

View Trial Details

Not Yet Recruiting

Plasma ctDNA Monitoring in Pediatric Acute Leukemia

NCT07751588

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hematologic Diseases, +12 more
Locations: Department of Pediatric Hematology/Oncology,Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China

View Trial Details

Not Yet Recruiting

Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.

NCT07518329

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations: Royal Adelaide Hospital Adelaide, South Australia, Australia

The Alfred Hospital Melbourne, Victoria, Australia

Epworth HealthCare Richmond, Victoria, Australia

St. Vincent's Hospital Sydney, New South Wales, Australia

View Trial Details

Not Yet Recruiting

Digital Patient-Reported Assessment in Older Adults With Acute Leukemia

NCT07597590

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: Hospital Universitario Central de Asturias (HUCA) Oviedo, Principality of Asturias, Spain

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions